These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36714342)

  • 1. A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera
    Han X; Zhang M; Wang H; Zhang Q; Li W; Hao M; Gao Y; Jin J; Ren H; Tang Y; Hong X; Ke X; Su H; Gui L; Luo J; Xie L; Gai W; Shi Y
    Chin J Cancer Res; 2022 Dec; 34(6):601-611. PubMed ID: 36714342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and safety of IBI301 versus rituximab in patients with CD20
    Jiang B; Ke X; Zhang Q; Xu W; Su H; Huang J; Zhang M; Wang H; Jin C; Zhu J; Liu L; Cai Z; Zhao X; Zhou J; Zhang X; Liu J; Zhou H; Yu J; Sun X; Qi J; Qiu L
    Sci Rep; 2020 Jul; 10(1):11676. PubMed ID: 32669656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera
    Shi Y; Zhang Q; Hong X; Wang Z; Gao Y; Zou L; Cen H; Gui L; Li Y; Feng J; Wang Z; Zhang M; Jin C; Zhang W; Hu J; Zheng C; Zheng Z; Zhang L; Chen S; Huang Y; Tang Y; Gao Y; Hao M; Li X; Chang C; Yang H; Wu H; Shen L; Ke X; Zhang L; Xi Y; Yang L; Xie L; Gai W; Ji Y
    Hematol Oncol; 2022 Dec; 40(5):930-940. PubMed ID: 35858181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma.
    Gui L; Han X; He X; Song Y; Yao J; Yang J; Liu P; Qin Y; Zhang S; Zhang W; Gai W; Xie L; Shi Y
    Chin J Cancer Res; 2016 Apr; 28(2):197-208. PubMed ID: 27199517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity of DRL_RI Versus Reference Rituximab in Biologics-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis: A Double-Blind, Randomized, Three-Arm Study.
    Haridas VM; Katta R; Nalawade A; Kharkar S; Zhdan V; Garmish O; Lopez-Lazaro L; Batra SS; Kankanwadi S
    BioDrugs; 2020 Apr; 34(2):183-196. PubMed ID: 32052313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 studies comparing safety, tolerability, pharmacokinetics and pharmacodynamics of HLX01 (a rituximab biosimilar) to reference rituximab in Chinese patients with CD20-positive B-cell lymphoma.
    Shi Y; Zhang Q; Han X; Qin Y; Ke X; Su H; Liu L; Fu J; Jin J; Feng J; Hong X; Zhang X; Wu D; Jiang B; Dong X
    Chin J Cancer Res; 2021 Jun; 33(3):405-416. PubMed ID: 34321836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, Double-Blind, Pharmacokinetic Equivalence Trial Comparing DRL-Rituximab With MabThera in Patients With Diffuse Large B-Cell Lymphoma.
    Viswabandya A; Shah S; Mukhopadhyay A; Nagarkar RV; Batra SS; Lopez-Lazaro L; Kankanwadi S; Srivastava A
    J Glob Oncol; 2019 Nov; 5():1-13. PubMed ID: 31809224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial comparing LY01011, biosimilar candidate, with the reference product denosumab (Xgeva®) in healthy Chinese subjects.
    Ding Y; Liu Y; Dou C; Guo S
    J Bone Oncol; 2023 Oct; 42():100499. PubMed ID: 37701913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera
    Sharman JP; Liberati AM; Ishizawa K; Khan T; Robbins J; Alcasid A; Rosenberg JA; Aurer I
    BioDrugs; 2020 Apr; 34(2):171-181. PubMed ID: 31820339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LZM008, a proposed tocilizumab biosimilar: Pharmacokinetics, safety, and immunogenicity profiles compared with ACTEMRA
    Cao G; Wang J; He J; Hu Y; Yang H; Que L; Gu X; Yu J; Wu X; Wu J; Fang W; He Q; Zhang J
    Front Pharmacol; 2023; 14():1111893. PubMed ID: 37081963
    [No Abstract]   [Full Text] [Related]  

  • 12. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis.
    Cohen S; Emery P; Greenwald M; Yin D; Becker JC; Melia LA; Li R; Gumbiner B; Thomas D; Spencer-Green G; Meng X
    Br J Clin Pharmacol; 2016 Jul; 82(1):129-38. PubMed ID: 26909489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tolerance and pharmacodynamics phase Ⅰ clinical trial study of chimeric anti-CD20 monoclonal antibody IBI301 in Chinese patients with CD20-positive non-Hodgkin's lymphoma].
    Jiang B; Qi JY; Sun MY; Li ZJ; Liu W; Liu LJ; Zhang FK; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2018 Apr; 39(4):320-324. PubMed ID: 29779330
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of teriparatide biosimilar with EU- and US-approved teriparatide reference products in healthy men and postmenopausal women.
    Fenwick S; Vekariya V; Patel R; Hajela P; Modi K; Kale P; Nath A
    Osteoporos Int; 2023 Jan; 34(1):179-188. PubMed ID: 36287230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized Phase 1 Pharmacokinetic Study Comparing the Potential Biosimilar LRG201902 With Liraglutide (Victoza
    Mai G; Fan L; Li M; Zhang P; Gan C; Huang Q; Shentu J
    Front Pharmacol; 2020; 11():610880. PubMed ID: 33584289
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial.
    Park W; Božić-Majstorović L; Milakovic D; Berrocal Kasay A; El-Khouri EC; Irazoque-Palazuelos F; Molina FFC; Shesternya P; Miranda P; Medina-Rodriguez FG; Wiland P; Jeka S; Chavez-Corrales J; Garmish O; Linde T; Rekalov D; Hrycaj P; Krause A; Fomina N; Piura O; Abello-Banfi M; Suh CH; Shim SC; Lee SJ; Lee SY; Kim SH; Yoo DH
    MAbs; 2018; 10(6):934-943. PubMed ID: 30010481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and Safety Comparison of Two Capecitabine Tablets in Patients with Colorectal or Breast Cancer Under Fed Conditions: A Multicenter, Randomized, Open-Label, Three-Period, and Reference-Replicated Crossover Study.
    Wang CJ; Li T; Lin PP; Tao Y; Jiang X; Li X; Wen Q; Cao Y
    Adv Ther; 2021 Sep; 38(9):4798-4814. PubMed ID: 34347254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Randomized, Double-Blind, Parallel-Group, Phase 1 Clinical Trial Comparing the Pharmacokinetic, Safety, and Immunogenicity of the Biosimilar HS016 and the Originator Adalimumab in Chinese Healthy Male Subjects.
    Cao G; Yu J; Wu J; Wang J; Xue Y; Yang X; Zhang J
    Clin Pharmacol Drug Dev; 2021 Mar; 10(3):317-325. PubMed ID: 32463599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach.
    Candelaria M; Gonzalez D; Fernández Gómez FJ; Paravisini A; Del Campo García A; Pérez L; Miguel-Lillo B; Millán S
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):515-527. PubMed ID: 29362903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.